MedPharm Research’s proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled “Isolation and pharmacological evaluation of phytocannabinoids for Alzheimer’s disease,” has been selected for funding.
Scoring of the proposal was organized into six categories: significance, approach, broader impacts, environment, data analysis, and environment. Reviewers from the ICR review panel concluded that the likelihood of the project to succeed is high, adding that minor cannabinoids is an area where more research is needed.
According to the Center for Disease Control, Alzheimer’s disease and related dementias are projected to grow to 13.9 million, nearly 3.3 percent of the population in 2060. Brains of people with Alzheimer’s show neurodegeneration and high levels of oxidative stress and inflammation.
“The study results will allow MedPharm to further develop innovative, bioavailable, and bioequivalent dosage forms. These are important elements in support of investigational new drugs (INDs) and new drug applications (NDAs) for future FDA-approved products,” stated Scott Karolchyk, MS, RPh, director of formulation and development.
The phytocannabinoid CBD has neuroprotective, antioxidant and anti-inflammatory properties. Other studies have shown that CBD has been shown to be effective in vivo, making the phytocannabinoid an interesting candidate for novel therapeutic interventions in Alzheimer’s therapy, especially because there are no psychoactive or cognition-impairing properties, thus adding to the significance of the MedPharm study.
Anticipated start date of the project is October 1, 2022.
Photo: Courtesy of Business Wire
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.